KR100910709B1 - 라베프라졸 나트륨염 무정형의 개선된 제조방법 - Google Patents
라베프라졸 나트륨염 무정형의 개선된 제조방법 Download PDFInfo
- Publication number
- KR100910709B1 KR100910709B1 KR1020070106499A KR20070106499A KR100910709B1 KR 100910709 B1 KR100910709 B1 KR 100910709B1 KR 1020070106499 A KR1020070106499 A KR 1020070106499A KR 20070106499 A KR20070106499 A KR 20070106499A KR 100910709 B1 KR100910709 B1 KR 100910709B1
- Authority
- KR
- South Korea
- Prior art keywords
- sodium salt
- labeprazole
- solvent
- amorphous
- rabeprazole
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims (5)
- 제 1 항에 있어서, 라베프라졸 나트륨염을 먼저 에스테르 용매로 용해하고, 이 용액을 탄소수가 홀수개인 알칸 용매에 가하여 라베프라졸 나트륨염 무정형을 제조하는 방법.
- 제 1 항에 있어서, 에스테르 용매의 사용량은 라베프라졸의 2~6배량을 사용하고, 탄소수가 홀수개인 알칸 용매의 사용량은 라베프라졸의 10~30배량을 사용하는 방법.
- 제 1 항에 있어서, 제조된 무정형의 라베프라졸 나트륨염의 잔류용매를 제거하기 위해 40~50℃에서 5~15시간 동안 진공건조하는 방법.
- 제 1 항에 있어서, 제조되는 라베프라졸 나트륨염 무정형의 평균 입자직경이 0.5~30㎛인 것.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070106499A KR100910709B1 (ko) | 2007-10-23 | 2007-10-23 | 라베프라졸 나트륨염 무정형의 개선된 제조방법 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070106499A KR100910709B1 (ko) | 2007-10-23 | 2007-10-23 | 라베프라졸 나트륨염 무정형의 개선된 제조방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20090041022A KR20090041022A (ko) | 2009-04-28 |
KR100910709B1 true KR100910709B1 (ko) | 2009-08-04 |
Family
ID=40764216
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020070106499A KR100910709B1 (ko) | 2007-10-23 | 2007-10-23 | 라베프라졸 나트륨염 무정형의 개선된 제조방법 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100910709B1 (ko) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011004281A1 (en) * | 2009-07-09 | 2011-01-13 | Alembic Limited | A process for the preparation of amorphous form of rabeprazole sodium |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004055001A2 (en) | 2002-12-16 | 2004-07-01 | Ranbaxy Laboratories Limited | Rabeprazole calcium |
EP1847538A1 (en) | 2006-04-21 | 2007-10-24 | Dipharma Francis S.r.l. | A process for the preparation of pyridine compounds |
-
2007
- 2007-10-23 KR KR1020070106499A patent/KR100910709B1/ko active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004055001A2 (en) | 2002-12-16 | 2004-07-01 | Ranbaxy Laboratories Limited | Rabeprazole calcium |
EP1847538A1 (en) | 2006-04-21 | 2007-10-24 | Dipharma Francis S.r.l. | A process for the preparation of pyridine compounds |
Non-Patent Citations (1)
Title |
---|
IN 2006DE01354 A |
Also Published As
Publication number | Publication date |
---|---|
KR20090041022A (ko) | 2009-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6050237B2 (ja) | グルホシネートp遊離酸の製造方法 | |
CA2904089C (en) | A process for sodium salt of (2s, 5r)-2-carboxamido-7-oxo-6-sulfooxy -1,6-diaza-bicyclo[3.2.1]octane | |
EP3444244B1 (en) | Preparation process for high-purity dabigatran etexilate | |
JP2024138039A (ja) | スフェンタニルクエン酸塩及びスフェンタニル塩基の調合 | |
EP2528912A1 (en) | Process for the preparation of crystalline forms of dexlansoprazole | |
KR100910709B1 (ko) | 라베프라졸 나트륨염 무정형의 개선된 제조방법 | |
KR101461259B1 (ko) | 톨루이딘 화합물의 제조 방법 | |
EP1869015A1 (en) | An improved process for the manufacture of rabeprazole sodium | |
CN116396312A (zh) | 一种枸橼酸艾沙佐米的制备方法 | |
JP5827684B2 (ja) | 2−[3−シアノ−4−(2−i−ブトキシ)フェニル]−4−メチル−5−チアゾール−カルボン酸(フェブキソスタット)の結晶形Aを調製するための方法 | |
EP2240496A2 (en) | Preparation of esomeprazole magnesium and hydrates thereof | |
EP2393771A1 (en) | Method for the synthesis of chiral alpha-aryl propionic acid derivatives | |
KR20190051850A (ko) | 무정형 디뉴클레오사이드 폴리포스페이트 화합물의 제조방법 | |
CA2483862A1 (en) | Process for the preparation of the amorphous form of atorvastatin calcium salt | |
JP4826133B2 (ja) | S−(−)−6−ヒドロキシ−2,5,7,8−テトラメチルクロマン−2−カルボン酸及びその製造方法 | |
WO2014195977A2 (en) | Novel polymorphs of vismodegib | |
AU2015259339B2 (en) | Method for preparation of silver azide | |
JP2004002230A (ja) | 微水ベンズイミダゾール系化合物の製法 | |
US20040242670A1 (en) | Process for preparation of amorphous atorvastatin calcium | |
JP2016531865A (ja) | ヒオデオキシコール酸ナトリウム(NaHDC)の多形形態およびその調製方法 | |
RU2741389C1 (ru) | Способ получения промежуточного соединения для синтеза лекарственного средства | |
JP2894525B2 (ja) | 結晶性テトラキス(トリフェニルホスフィン)パラジウム及びその製造法 | |
AU4030101A (en) | Anhydrous mirtazapine and process for preparing the same | |
WO2008146297A2 (en) | Improved process for amorphous rabeprazole sodium | |
JP6433809B2 (ja) | 1−(3−ヒドロキシメチルピリジル−2−)−2−フェニル−4−メチルピペラジンの製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130709 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20140702 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20150708 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20160714 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20170620 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20180625 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20190620 Year of fee payment: 11 |